 |
 |
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Control of Lipids in Patients with Type 2 Diabetes: Recommendations from the American College of Physicians
20 April 2004 | Volume 140 Issue 8 | Page I-85
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full reports titled "Lipid Control in the Management of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians" and "Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians." They are in the 20 April 2004 issue of Annals of Internal Medicine (volume 140, pages 644-649 and pages 650-658). The authors of the first report are V. Snow, M.D. Aronson, E.R. Hornbake, C. Mottur-Pilson, and K.B. Weiss, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians; the authors of the second report are S. Vijan and R.A. Hayward.
Who developed these guidelines?
The American College of Physicians developed these recommendations. Members of the College are internists, specialists in the care of adults.
What is the problem and what is known about it so far?
Diabetes mellitus is a common disease that interferes with the body's ability to store energy from food. The pancreas makes a substance called insulin that helps to store energy from food. In type 2 diabetes (also called adult-onset diabetes), the body makes plenty of insulin but is unable to use it normally. The result is high blood sugar levels that, over time, can lead to complications that include blindness, kidney failure, nerve damage, and cardiovascular disease (heart attacks and strokes). While good blood sugar control can prevent the development of most of these complications, it does not prevent the development of cardiovascular disease. The control of lipids (cholesterol and other fats in the blood) is very important in preventing the cardiovascular complications of type 2 diabetes.
How did the American College of Physicians develop these recommendations?
The authors reviewed studies about lipid-lowering drugs and cardiovascular complications in people with type 2 diabetes. They used these studies to identify the benefits of lipid control in 2 groups of people with diabetes: those who had already developed cardiovascular disease and those who had not. They also collected information about the side effects of lipid-lowering drugs.
What did the authors find?
The authors found 8 high-quality studies of lipid-lowering drugs in patients with type 2 diabetes and known cardiovascular disease and 6 studies in patients who did not yet have cardiovascular disease. Lipid-lowering drugs decreased the chances of developing future cardiovascular events, such as heart attacks or strokes, in both groups. Most of the trials had used moderate doses of drugs called statins to lower lipids. The studies did not provide definite answers about the lipid levels at which treatment should start or the levels to aim for with treatment. Generally, they showed that the lower the level of low-density lipoprotein cholesterol (bad cholesterol), the better. Severe liver or muscle side effects of the statins were rare.
What does the American College of Physicians recommend that patients and doctors do?
Men and women with type 2 diabetes should be receiving lipid-lowering treatment regardless of whether they have or do not yet have cardiovascular disease. Since available studies do not provide good information about the best cholesterol levels for people with type 2 diabetes, patients and doctors should consider lipid-lowering drugs regardless of patients' lipid levels. Moderate doses of drugs called statins are the lipid-lowering drugs of choice for patients with type 2 diabetes. Doctors do not need to monitor liver function and muscle enzyme tests for patients taking statins unless patients develop symptoms of liver or muscle disease.
What are the cautions related to these recommendations?
Recommendations may change as new studies become available. Some patients may not be able to tolerate statins because of side effects. For these patients, the risks of statins may outweigh their benefits. Doctors should consider other ways to control lipids in such patients.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  B. T. Denton, M. Kurt, N. D. Shah, S. C. Bryant, and S. A. Smith Optimizing the Start Time of Statin Therapy for Patients with Diabetes Med Decis Making, May 1, 2009; 29(3): 351 - 367. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Gao and G. E. Mann Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling Cardiovasc Res, April 1, 2009; 82(1): 9 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nagy, J. Watine, P. S. Bunting, R. Onody, W. P. Oosterhuis, D. Rogic, S. Sandberg, K. Boda, and A. R. Horvath Do Guidelines for the Diagnosis and Monitoring of Diabetes Mellitus Fulfill the Criteria of Evidence-Based Guideline Development? Clin. Chem., November 1, 2008; 54(11): 1872 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. White Jr Do People With Diabetes Need Statins? The Diabetes Educator, July 1, 2008; 34(4): 664 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Goldberg and T. A. Jacobson Effects of Niacin on Glucose Control in Patients With Dyslipidemia Mayo Clin. Proc., April 1, 2008; 83(4): 470 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Nesto LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach? Clin. Diabetes, January 1, 2008; 26(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Ohman-Strickland, A. J. Orzano, S. V. Hudson, L. I. Solberg, B. DiCiccio-Bloom, D. O'Malley, A. F. Tallia, B. A. Balasubramanian, and B. F. Crabtree Quality of Diabetes Care in Family Medicine Practices: Influence of Nurse-Practitioners and Physician's Assistants Ann. Fam. Med, January 1, 2008; 6(1): 14 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdmann Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 211 - 216. [Abstract] [PDF]
|
|
|
|
 |
|
 A. J. Weymiller, V. M. Montori, L. A. Jones, A. Gafni, G. H. Guyatt, S. C. Bryant, T. J. H. Christianson, R. J. Mullan, and S. A. Smith Helping Patients With Type 2 Diabetes Mellitus Make Treatment Decisions: Statin Choice Randomized Trial Arch Intern Med, May 28, 2007; 167(10): 1076 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Grant and J. B. Meigs Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction Diabetes Care, March 1, 2007; 30(3): 479 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hayward, T. P. Hofer, and S. Vijan Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med, October 3, 2006; 145(7): 520 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ahmed, C. P. Cannon, S. A. Murphy, and E. Braunwald Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial Eur. Heart J., October 1, 2006; 27(19): 2323 - 2329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Mittleman A 39-year-old woman with hypercholesterolemia. JAMA, July 19, 2006; 296(3): 319 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Donnan, L. Donnelly, J. P. New, and A. D. Morris Derivation and Validation of a Prediction Score for Major Coronary Heart Disease Events in a U.K. Type 2 Diabetic Population. Diabetes Care, June 1, 2006; 29(6): 1231 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. van Weel, M. de Vries, P. J. Voshol, R. E. Verloop, P. H.C. Eilers, V. W.M. van Hinsbergh, J. H. van Bockel, and P. H.A. Quax Hypercholesterolemia Reduces Collateral Artery Growth More Dominantly Than Hyperglycemia or Insulin Resistance in Mice Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1383 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Costa, M. Borges, C. David, and A. Vaz Carneiro Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials BMJ, May 13, 2006; 332(7550): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wartofsky Update in Endocrinology Ann Intern Med, November 1, 2005; 143(9): 673 - 682. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Harris Elevated Liver Function Tests in Type 2 Diabetes Clin. Diabetes, July 1, 2005; 23(3): 115 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Nerurkar, L. Pearson, J. T. Efird, K. Adeli, A. G. Theriault, and V. R. Nerurkar Microsomal Triglyceride Transfer Protein Gene Expression and ApoB Secretion Are Inhibited by Bitter Melon in HepG2 Cells J. Nutr., April 1, 2005; 135(4): 702 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rodriguez-Manas, M. Castro, and J. Manzarbeitia Review: Cardiovascular risk and diabetes in old people The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 7 - 11. [Abstract] [PDF]
|
|
|
|
|
|
S. Gottlieb Patients with type 2 diabetes should take statins BMJ, May 8, 2004; 328(7448): 1095. [Full Text]
|
|
|
|
 |
|
 ACP Recommends Lipid-lowering Therapy for Primary and Secondary Prevention of CHD in Type 2 Diabetes Journal Watch (General), May 7, 2004; 2004(507): 4 - 4. [Full Text]
|
|
Read all Rapid Responses
Article
